Farlong Nutraceutical has conducted a 90-day double blind, randomised, placebo controlled, parallel study to determine the safety and efficacy of Farlong Lifeflower Breviscapine on improving long and short-term memory, concentration, and clarity of thinking in healthy individuals.
Conducted by clinician Melanie Montgomery, Ph.D., of Clinical Studies USA, the partially grant-funded study consisted of 160 healthy individuals divided into four study groups, with the first given one placebo capsule twice daily, and the other three groups receiving different daily doses of Farlong Lifeflower Breviscapine – 100 mg, 200 mg, and 400 mg each. Every 30 days, subjects were given three separate evaluations to assess their cognitive thinking, concentration, clarity of thought and general brain functions, along with having vital signs checked and blood work analysed.
Upon conclusion of the 90-day period, an expert panel committee concluded that Lifeflower Breviscapine was shown to be safe, effective, and well tolerated with no negative impact on any organs or systems, and no interactions, sensitivities, or side effects reported during the study. The expert panel committee concluded that Lifeflower enhances the pharmacological effects of Erigeron Breviscapus and its active ingredients for the treatment of Alzheimer's disease, metabolism, and the pharmacological mechanisms of active ingredients.
Scutellarin has been shown to enhance memory, cognitive function and brain health; increase brain circulation
The most significant positive impacts were seen in the MEM Trax cognitive thinking tests that were given – a psychological test designed to measure a person’s cognitive abilities and intellectual potential that was developed to test the type of memory most associated with Alzheimer’s disease and dementia.
Participants also experienced positive changes over the 90 days in their A1c; Mini-Mental Status Exam (MMSE), a cognitive screening tool that provides a brief, objective measure of cognitive function; and during their Montreal Cognitive Assessment (MoCA), a brief, 30-question test that helps healthcare professionals detect cognitive impairments very early on, allowing for faster diagnosis and patient care.
The study was also peer-reviewed by M. Rubin MD, who believes the results are accurate and supported scientifically, making Lifeflower Breviscapine a safe and effective product for human uses. He concluded that this study designates the best dose for Lifeflower Breviscapine and that all necessary blood work was completed to indicate this product should produce no significant side effects.
Lifeflower Breviscapine is an active flavonoid component extracted from Erigeron Breviscapus, containing more than 90 percent of scutellarin. Scutellarin has been shown to enhance memory, cognitive function and brain health; increase brain circulation; and promote the development of new blood vessels. A series of safety and efficacy studies were conducted, and an expert panel committee concluded that Lifeflower Breviscapine manufactured consistent with cGMP (Current Good Manufacturing Practice) is GRAS (generally recognised as safe) for use as an ingredient in yoghurt, nutritional bars, smoothies at 84 mg per serving, and dietary supplements at 200 mg per person per day.
